Dermatology.
Dover
J S
JS
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA.
Arndt
K A
KA
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D003880:Dermatology / Q000639:trends*; D003881:Dermatomycoses / Q000188:drug therapy; D000077595:Famciclovir; D006561:Herpes Simplex / Q000188:drug therapy; D006562:Herpes Zoster / Q000188:drug therapy; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D009260:Nail Diseases / Q000188:drug therapy; D009281:Naphthalenes / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use; D012871:Skin Diseases / Q000628:therapy*; D000077291:Terbinafine; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000935:Antifungal Agents; D000998:Antiviral Agents; D003879:Dermatologic Agents; D009281:Naphthalenes; D011355:Prodrugs; D017964:Itraconazole; D015075:2-Aminopurine; D000077291:Terbinafine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir